coronary atherosclerotic heart disease CAHD CAHD CAHD CAHD

Transcript

1 CJITWM November 2013 Vol. 33 No therapeutic angiogenesis coronary atherosclerotic heart disease CAHD CAHD CAHD CAHD CAHD CAHD Activating Blood Circulation to Remove Stasis and Therapeutic Angiogenesis of Coronary Heart Disease DUAN Lian XIONG Xing-jiang and WANG Jie Department of Cardiology Guang' anmen Hospital China Academy of Chinese Medical Sciences Beijing China ABSTRACT Therapeutic angiogenesis comes into sight as a new strategy for coronary atherosclerotic heart disease CAHD. The therapeutic method of activating blood circulation to remove stasis has shown confirmative effect upon both fundamental researches and clinical trials of CAHD. Thus the new proposition may provide a better treatment plan for CAHD to study on therapeutic angiogenesis with the therapeutic method of activating blood circulation to remove stasis. The author reviewed relevant theories and the latest researches on the basis of combining diseases identification and syndrome typing discussed the state quo and achievement of therapeutic angiogenesis in CAHD by Chinese herbal medicines CHM of activating blood circulation to remove stasis from fundamental and clinical researches and action mechanisms from standpoints of Chinese herbal compounds single Chinese herb effective herbal chemical composition thus providing references for future researches. KEYWORDS coronary heart disease therapeutic angiogenesis activating blood circulation to remove stasis coronary atherosclerotic 2 heart disease CAHD 3 β - CAHD therapeutic angiogenesis CAHD CAHD 1 33% Tel wangjie0103@ yahoo. com. cn DOI /CJIM Isner JM angiogenesis arteriogenesis vasculogenesis 5

2 CJITWM November 2013 Vol. 33 No. 11 IGF-1 PDGF VEGF HenryTD VEGF VEGF en- dothelial progenitor cells EPCs EPCs VEGF FGF vascular endothelial growth factor VEGF fibroblast growth factor FGF insulin-like growth factor IGF platelet-derived growth factor PDGF 2 VEGF FGF CAHD VEGF α hypoxia inducible fac- 8 tor HIF-1α VEGF 9 VEGF mrna HIF-1α 11 CAHD CAHD 18 HIF-1α VEGF 19 CAHD 20 FGF 21 FGF 9 bfgf 12 22

3 CJITWM November 2013 Vol. 33 No bfgf 15 g 10 g 12 g 5 VEGF bfgf ECV ECV304 percutaneous transluminal coronary angioplasty PTCA VEGF 34 ECV304 DNA DNA VEGF mrna CAHD VEGF 20 g 15 g ECV g 10 g 5 g 8 g 10 g g 10 g 15 g 10 g 8 g g VEGF ECV304 3 VEGF FGF TGFb TNFa 28 VEGF FGF TNFa TGFb VEGF bfgf CAM CAM ecdysterone EDS bfgf CAM EDS 7 EDS

4 CJITWM November 2013 Vol. 33 No Folkman VEGF A hydroxylsafflor yellow A HSYA VEGF mrna HIF-1α HSYA VEGF 40 VEGF /VEGF 41 ECV304 VEGF mrna 42 VEGF ECV FGF 44 VEGF CAHD CD34 CAHD CAHD 3 CAHD CAHD 43 CAHD CAHD CAHD 51 VEGF bfgf

5 CJITWM November 2013 Vol. 33 No Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia J. Angiogenesis Liu Y Cox SR Morita T et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer J. Circ Res CAHD 11 Liu LX Lu H Luo Y et al. Stabilization of vascular endothelial growth factor mrna by hypoxia-inducible factor 1 1 Braim M. Rahel Maarten J. Suttorp Gert J. Laarman et al. Primary stenting of occluded native coronary arteries final results of the primary stenting of occluded native coronary arteries PRISON study J. Am Heart J Jean L. Rouleau. New and emerging drugs and device therapies for chronic heart failure in patients with systolic ventricular dysfunction J. Can J Cardiol Hayward PA Zhu YY Nguyen TT et al. Should all moderate coronary lesions be grafted during primary coronary by pass surgery An anlysis of progression of native vessel disease during a randomized trial of conduits J. J Thorac Cardiovasc Surg Isner JM Rosenfield K Losordo DW et al. Percutaneous intravascular US as adjunct to catheter-based interventions preliminary experience in patients with peripheral vascular disease J. Radiology O'Reilly MS Holmgren L Shing Y et al. Angiostatin a novel angiogenesis inhibitor that mediates the suppression of metasis by a Lewis lung carcinoma J. Cell Niels van Royen Jan J. Piek Ivo Buschmann et al. Stimulation of arteriogenesis a new concept for the treatment of arterial occlusive disease J. Cardiovasc Res Takayuki Asahara Haruchika Masuda Tomono Takahashi et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization circulation research J. Circ Res Tirziu D Simons M. Angiogenesis in the human heart gene and cell therapy J. Angiogenesis J. Biochem Biophys Res Commun Folkman J Klagsbrun M. Angiogenic factors J. Science Hocke l. Angiotropin treatment prevents flap necrosis and enhances dermal regeneration in rabbits J. Arch Surg J Simons M Annex BH Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2 a double-blind randomized controlled clinical trial J. Circulation Kleiman NS Califf RM. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC American College of Cardiology J. J Am Coll Cardiol J J N J Wang J Xiong XJ. Current situation and perspectives of clinical study in integrative medicine in China J. Evid- Based Complement Alternat Med M J J

6 CJITWM November 2013 Vol. 33 No J J IL-6 VEGF D. 40 Ji DB Zhu MC Zhu B et al. Hydroxyl safflor yellow A Wang J Xiong XJ. Outcome measures of Chinese herbal medicine for hypertension an overview of systematic reviews enhances survival of vascular endothelial cells under hypoxia via up-regulation of the HIF-1α-VEGF pathway and regulation of Bcl-2 /Bax J. J Cardiovasc Pharmacol 2008 J. Evid Based Complement Alternat Med promotes vascular endothelial cell proliferation via VEGF / J. VEGF receptor J. J Chin Pharmac Sci J. ECV304 J J. D Simons M Bonow RO Chronos NA et al. Clinical trials D in coronary angiogenesis issues problems consensus an 31. expert panel summary J. Circulation E73-E86. J J. 32. ECV J ECV304 J J ECV304 J J Wang J Xiong XJ. Current situation and perspectives of 35. clinical study in integrative medicine in China J. Evid- HIF-1α VEGF J. Based Complement Alternat Med J D J AMI HUVEC D. 41 Song Y Zhang L Qu K et al. Hydroxy safflor yellow A D HPLC J